Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?The Motley Fool • 12/22/23
6 Words That Explain Why CRISPR Stock Isn't Soaring Despite the Recent FDA Approval for Its Gene-Editing TherapyThe Motley Fool • 12/21/23
Here's the 1 Key Reason You Might Want to Buy CRISPR Therapeutics Stock on the DipThe Motley Fool • 12/16/23
Here's What The FDA Approval Of Gene Editing For Sickle Cell Means For CRSP Stock And The Future Of MedicineInvestors Business Daily • 12/12/23
After Golden Cross, CRISPR Therapeutics AG (CRSP)'s Technical Outlook is BrightZacks Investment Research • 12/11/23